BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 3891854)

  • 21. Tissue distribution and tumor localization of effector cells in adoptive immunotherapy of cancer.
    Basse PH
    APMIS Suppl; 1995; 55():1-28. PubMed ID: 8534522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Administration of recombinant human IL-7 to mice alters the composition of B-lineage cells and T cell subsets, enhances T cell function, and induces regression of established metastases.
    Komschlies KL; Gregorio TA; Gruys ME; Back TC; Faltynek CR; Wiltrout RH
    J Immunol; 1994 Jun; 152(12):5776-84. PubMed ID: 8207207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
    Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
    Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interleukin-2 administered in vivo induces the growth and augments the function of cultured T cells in vivo.
    Cheever MA; Thompson JA; Kern DE; Greenberg PD
    J Biol Response Mod; 1984 Oct; 3(5):462-7. PubMed ID: 6334133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma.
    Donohue JH; Rosenstein M; Chang AE; Lotze MT; Robb RJ; Rosenberg SA
    J Immunol; 1984 Apr; 132(4):2123-8. PubMed ID: 6607956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
    Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
    Lafreniere R; Rosenberg SA
    J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
    Shu S; Krinock RA; Matsumura T; Sussman JJ; Fox BA; Chang AE; Terman DS
    J Immunol; 1994 Feb; 152(3):1277-88. PubMed ID: 8301131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Donor T cells can be induced to grow and survive long term in vivo without previous host immunosuppression.
    Chen W; Cheever MA
    J Immunol; 1994 May; 152(10):4767-74. PubMed ID: 8176202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
    Bristol JA; Schlom J; Abrams SI
    Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antigen-specific Il-4- and IL-10-secreting CD4+ lymphocytes increase in vivo susceptibility to Trypanosoma cruzi infection.
    Barbosa de Oliveira LC; Curotto de Lafaille MA; Collet de Araujo Lima GM; de Almeida Abrahamsohn I
    Cell Immunol; 1996 May; 170(1):41-53. PubMed ID: 8660798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence for the involvement of Fas ligand and perforin in the induction of vascular leak syndrome.
    Rafi AQ; Zeytun A; Bradley MJ; Sponenberg DP; Grayson RL; Nagarkatti M; Nagarkatti PS
    J Immunol; 1998 Sep; 161(6):3077-86. PubMed ID: 9743374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decrease in interleukin 2-induced vascular leakage in the lungs of mice by administration of recombinant interleukin 1 alpha in vivo.
    Puri RK; Travis WD; Rosenberg SA
    Cancer Res; 1989 Feb; 49(4):969-76. PubMed ID: 2783561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens. Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines.
    Rodolfo M; Zilocchi C; Melani C; Cappetti B; Arioli I; Parmiani G; Colombo MP
    J Immunol; 1996 Dec; 157(12):5536-42. PubMed ID: 8955204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NTP Toxicology and Carcinogenesis Studies of Pentachloroanisole (CAS No. 1825-21-4) in F344 Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Apr; 414():1-284. PubMed ID: 12616284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic administration of IL-2 induces lymphokine-activated killer (LAK) cells capable of killing macrophages in various tissues.
    Kamitani T; Suzuki H; Yano S
    Immunology; 1989 Dec; 68(4):520-5. PubMed ID: 2606510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
    Hwu P; Yang JC; Cowherd R; Treisman J; Shafer GE; Eshhar Z; Rosenberg SA
    Cancer Res; 1995 Aug; 55(15):3369-73. PubMed ID: 7614473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2.
    Rosenthal NS; Hank JA; Kohler PC; Minkoff DZ; Moore KH; Bechhofer R; Hong R; Storer B; Sondel PM
    J Biol Response Mod; 1988 Apr; 7(2):123-39. PubMed ID: 3258904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.